23ZR1453500，IL-33调控EOMES+Tr1样细胞分化介导EGFR突变肺癌免疫逃逸的机制研究，上海市科学技术委员会，202304至202603，200000，主持

上海市“医苑新星”青年医学人才培养计划，上海市卫健委，202001-202306，100000，主持

81703020，TRIM21通过调控PD-L1表达对非小细胞肺癌的放疗增敏 作用及其机制研究，国家自然科学基金委员会，201801至202012，190000，主持

LncRNA HOTAIR作为ceRNA通过调节PTEN介导EGFR-TKI耐药的机制研究，上海市科学技术委员会，201606至201906，200000，主持

1. Zhou F, Sun J, Ye L, Jiang T, Li W, Su C, Ren S, Wu F, Zhou C, Gao G. Fibronectin promotes tumor angiogenesis and progression of non-small-cell lung cancer by elevating WISP3 expression via FAK/MAPK/ HIF-1α axis and activating wnt signaling pathway. Exp Hematol Oncol. 2023 Jul 19;12(1):61.

2. Zhou F, Yang Y, Zhang L, Cheng Y, Han B, Lu Y, Wang C, Wang Z, Yang N, Fan Y, Wang L, Ma Z, Zhang L, Yao Y, Zhao J, Dong X, Zhu B, Zhou C. Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors. ESMO Open. 2023 Jun;8(3):101560.

3. Zhou F, Zhou C. Notch Mutations as a Novel Biomarker for Immunotherapy. J Thorac Oncol. 2023 May;18(5):e54-e56.

4. Zhou F, Guo H, Zhou X, Xie H, Tian T, Zhao W, Gao G, Xiong A, Wang L, Li W, Chen X, Zhang Y, Fan J, Wu F, Zhang Y, Zhou C. Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study. Ther Adv Med Oncol. 2022 Nov 14;14:17588359221136759.

5. Zhou F, Zhou C. Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors. J Thorac Oncol. 2021 Oct;16(10):1622-1626. 

6. Zhou F#, Huang Y#, Cai W#, Li J#, Su C, Ren S, Wu C*, Zhou C*. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients. Lung Cancer. 2021 Mar;153:66-72.

7. Sun K, You A, Wang B, Song N, Wan Z, Wu F, Zhao W, Zhou F*, Li W*. Clinical T1aN0M0 lung cancer: differences in clinicopathological patterns and oncological outcomes based on the findings on high-resolution computed tomography. Eur Radiol. 2021 Oct;31(10):7353-7362. 

8. Zhou F#, Qiao M#, Zhou C*. The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol. 2021 Feb;18(2):279-293. doi: 10.1038/s41423-020-00577-5.

9. Wang H#, Zhou F#, Qiao M, Li X, Zhao C, Cheng L, Chen X, Zhou C. The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Front Oncol. 2021 Jul 21;11:671874. 

10. Mao S#, Zhou F#, Liu Y, Yang S, Chen B, Xu J, Wu F, Li X, Zhao C, Wang W, Liu Q, Yu X, Jia K, Shao C, Zhou C, Gao G, Ren S. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. Cancer Immunol Immunother. 2022 Jan;71(1):219-228.

11. Ye L#, Chen X#, Zhou F*. EGFR-mutant NSCLC: emerging novel drugs. Curr Opin Oncol. 2021 Jan;33(1):87-94. doi: 10.1097/CCO.0000000000000701.

12. Zhang H#, Zhou F#, Wang Y#, Xie H#, Luo S, Meng L, Su B, Ye Y, Wu K, Xu Y*, Gong X*. Eliminating Radiation Resistance of Non-Small Cell Lung Cancer by Dihydroartemisinin Through Abrogating Immunity Escaping and Promoting Radiation Sensitivity by Inhibiting PD-L1 Expression. Front Oncol. 2020 Oct 28;10:595466. doi: 10.3389/fonc.2020.595466.

13. Zhou F#, Zhao W#, Gong X#, Ren S, Su C, Jiang T*, Zhou C*. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer. J Immunother Cancer. 2020 Sep;8(2):e001300.

14. Zhou F, Zhou C*. Treatment Algorithm for Advanced ALK-Rearranged NSCLC: Reply. J Thorac Oncol. 2020 Sep;15(9):e157-e158. doi: 10.1016/j.jtho.2020.06.005.

15. Zhou F, Zhou C*. Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a Sprint. J Thorac Oncol. 2020 Apr;15(4):485-488. doi: 10.1016/j.jtho.2019.12.130.

16. Liu S#, Zhou F#, Liu Z#, Xiong A, Jia Y, Zhao S, Zhao C, Li X, Jiang T, Han R, Qiao M, Liu Y, He Y, Li J, Li W, Gao G, Ren S, Su C, Zhou C*. Predictive and prognostic significance of M descriptors of the 8th TNM classification for advanced NSCLC patients treated with immune checkpoint inhibitors. Transl Lung Cancer Res. 2020 Aug;9(4):1053-1066.

17. Chen X#, Zhou F#, Li X, Yang G, Zhao C, Li W, Wu F, Yu J, Gao G, Li J, Li A, Ren S, Zhou C*. Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer. Ann Transl Med. 2020 May;8(10):631.

18. Zhou J#, Zhou F#, Xie H, Wu Y, Zhao J, Su C*. An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: a case report. Transl Lung Cancer Res. 2020 Apr;9(2):354-359.

19. Zhou J#, Zhou F#, Chu X#, Zhao J, Wu Y, Zhao W, Xu C*, Su C*. Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases. Transl Lung Cancer Res. 2020 Apr;9(2):316-324.

20. Shi M#, Zhao W#, Zhou F#, Chen H, Tang L, Su B*, Zhang J*. Neutrophil or platelet-to-lymphocyte ratios in blood are associated with poor prognosis of pulmonary large cell neuroendocrine carcinoma. Transl Lung Cancer Res. 2020 Feb;9(1):45-54.

21. Gao G#, Jia K#, Zhao S#, Li X, Zhao C, Jiang T, Su C, Ren S, Zhou F*, Zhou C*. Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer. Transl Lung Cancer Res. 2019 Dec;8(6):920-928.

22. Zhou F#, Zhao W#, Chen X, Zhang J*, Zhou C. Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAFV600E mutation. Lung Cancer. 2020 Jan;139:219-220.

23. Li W#, Zhou F#, Wan Z, Li M, Zhang Y, Bao X, Zhang L*, Shi J*. Clinicopathologic features and lymph node metastatic characteristics in patients with adenocarcinoma manifesting as part-solid nodule exceeding 3 cm in diameter. Lung Cancer. 2019 Oct;136:37-44.

24. Zhang J#, Zhou F#, Qi H#, Ni H, Hu Q, Zhou C*, Li Y, Baburina I, Courtney J, Salamone SJ. Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. Br J Clin Pharmacol. 2019 Oct;85(10):2292-2301.

25. Pan Y#, Gao G#, Chen X#, Tian Q, Wu F, Liu Q, Wang Y, Jiang T, Liu Y, Li X, Yang S, Xu C, Su C, Zhou F*, Ren S* Zhou C. Larger Tumor is associated with Inferior PFS of First-Line EGFR-TKI and has numerically lower abundance of EGFR mutation in Patients with Advanced NSCLC. Thoracic Cancer (2019), doi: 10.1111/1759-7714.12986.

26. Wu T#, Zhou F#, Soodeen-Lalloo AK, Yang X, Shen Y, Ding X, Shi J, Dai J, Shi J, The association between imaging features of TSCT and the expression of PD-L1 in patients withsurgical resection of lung adenocarcinoma, Clinical Lung Cancer (2018), doi:https://doi.org/10.1016/j.cllc.2018.10.012.

27. Zhou F#, Ma W#, Li W#, Ni H, Gao G, Chen X*, Zhang J*, Shi J*. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs. BMC Cancer. 2018 Oct 23;18(1):1033. doi: 10.1186/s12885-018-4938-9

28. Jiang T#, Chu Q#, Wang H#, Zhou F#, Gao G#, Chen X, Li X, Zhao C, Xu Q, Li W, Wu F, Xiong A, Zhao J, Xu Y, Su C, Ren S, Zhou C*, Hirsch FR. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. Int J Cancer. 2018 Nov 2. doi: 10.1002/ijc.31962.

29. Zhou F, Zhou C. Lung cancer in never smokers—the East Asian experience. Transl Lung Cancer Res 2018. doi: 10.21037/tlcr.2018.05.14

30. Xu Q#, Zhou F#, Liu H#, Jiang T, Li X, Xu Y, Zhou C. Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs. J Thorac Oncol. 2018 May 28. pii: S1556-0864(18)30632-4.

31. Zhou F#, Hou L#, Ding T#, Song Q, Chen X, Su C, Li W, Gao G, Ren S, Wu F, Fan J, Wu C, Zhang J*, Zhou C*. Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells? Lung Cancer. 2018 Feb;116:30-37.

32. Su C#, Zhou F#, Shen J, Zhao J, O'Brien M*. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge. Eur J Cancer. 2017 Sep;83:266-278.

33. Gu Y#, Shi H#, Su C, Chen X, Zhang S, Li W, Wu F, Gao G, Wang H, Chu H, Zhou C, Zhou F*, Ren S*.The role of endobronchial ultrasound elastography in the diagnosis of mediastinal and hilar lymph nodes. Oncotarget. 2017 Jul 6;8(51):89194-89202.

34. Liu Y#, Sun H#, Zhou F#, Su C, Gao G, Ren S, Zhou C, Zhang Z*, Shi J*. Imaging features of TSCT predict the classification of pulmonary preinvasive lesion, minimally and invasive adenocarcinoma presented as ground glass nodules. Lung Cancer. 2017 Jun;108:192-197.

35. Ding T#, Zhou F#, Chen X, Zhang S, Liu Y, Sun H, Ren S, Li X, Zhao C, Wang H*, Zhou C*. Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations. J Thorac Dis. 2017 Sep;9(9):2923-2934.

36. Chen K#, Zhou F#, Shen W#, Jiang T, Wu X, Tong X, Shao YW, Qin S*, Zhou C*. Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. J Thorac Oncol. 2017 Jan 16. pii: S1556-0864(17)30010-2.

37. Zhou F, Zhou CC*. Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough. Chin J Cancer. 2015 Jul 18;34:31. doi: 10.1186/s40880-015-0036-4.

38. Zhou F, Jiang T, Ma W, Gao G, Chen X, Zhou C*. The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis. Lung Cancer. 2015 Aug;89(2):203-11. doi: 0.1016/j.lungcan.2015.06.005.

39. Zhou F, Zhou C*. Necitumumab for patients with non-squamous NSCLC: uninspiring results. Lancet Oncol. 2015 Mar;16(3):246-7. doi: 10.1016/S1470-2045(15)70059-8. 

40. Zhou F, Chen X, Zhou C*. Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors in Lung Cancer Patients With EGFR Wild-Type Tumors: When There Is a Target, There Is a Targeted Drug. J Clin Oncol. doi: 10.1200/JCO.2014.57.5449.

41. Zhou F, Zhou CC*. Advances in the management of acquired resistance to EGFR-TKI in non-small cell lung cancer. Oncol Transl Med. 2015 Vol. 1, No. 1. 20-25.

42. Liu L#, Zhou F#, Ren S, Chen X, Li X, Li W, Zhou C*. Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Asia Pac J Clin Oncol. 2014 Aug 17.doi: 10.1111/ajco.12258.

43. Zhou F, Chen X, Zhou C*. How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? J Thorac Oncol. 2014 Feb; 9(2):e19-20.doi: 0.1097/JTO.0000000000000046.

44. Zhou F, Gao G, Ren S, Li X, He Y, Zhou C*. The association between COX-2 polymorphisms and hematologic toxicity in patients with advanced non-small-cell lung cancer treated with platinum-based chemotherapy. PLoS One. 2013 Apr 19; 8(4):e61585.doi: 10.1371/journal.pone.0061585.